VRTX · Earnings call · 2026Q3T · Full report

VX-017 Type 1 Diabetes Opportunity

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 33 · Surprise 42

Vertex prioritized VX-017 as its lead type 1 diabetes cell-therapy program, describing it as an allogeneic, off-the-shelf, glucose-responsive insulin-producing therapy. Unlike zimislecel, VX-017 is designed for people with all blood types, which management said doubles the eligible patient population to approximately 120,000. Patients had begun dosing in a Phase 1/2 study, while near-term priorities include demonstrating proof of concept and scaling manufacturing ahead of potential pivotal development.

Key facts

• Vertex selected VX-017 as its lead type 1 diabetes program and began dosing patients in a Phase 1/2 study.
• Vertex's near-term VX-017 goals are proof of concept and scaling manufacturing, with a goal of moving to pivotal development in 2027.
• VX-017 is designed for people with all blood types, doubling the eligible patient population to about 120,000 people.